IgA antigliadin antibodies as a possible marker for IgA mesangial glomerulonephritis in adults with primary glomerulonephritis. 1989

G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue

UI MeSH Term Description Entries
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D010940 Plant Proteins Proteins found in plants (flowers, herbs, shrubs, trees, etc.). The concept does not include proteins found in vegetables for which PLANT PROTEINS, DIETARY is available. Plant Protein,Protein, Plant,Proteins, Plant
D005903 Gliadin Simple protein, one of the prolamines, derived from the gluten of wheat, rye, etc. May be separated into 4 discrete electrophoretic fractions. It is the toxic factor associated with CELIAC DISEASE. alpha-Gliadin,alpha Gliadin
D005921 Glomerulonephritis Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. Bright Disease,Kidney Scarring,Glomerulonephritides,Scarring, Kidney
D005922 Glomerulonephritis, IGA A chronic form of glomerulonephritis characterized by deposits of predominantly IMMUNOGLOBULIN A in the mesangial area (GLOMERULAR MESANGIUM). Deposits of COMPLEMENT C3 and IMMUNOGLOBULIN G are also often found. Clinical features may progress from asymptomatic HEMATURIA to END-STAGE KIDNEY DISEASE. Berger Disease,Immunoglobulin A Nephropathy,Nephropathy, IGA,Berger's Disease,IGA Glomerulonephritis,IGA Nephropathy,Iga Nephropathy 1,Nephritis, IGA Type,Bergers Disease,Glomerulonephritides, IGA,IGA Type Nephritis,Nephropathy 1, Iga,Nephropathy, Immunoglobulin A
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000906 Antibodies Immunoglobulin molecules having a specific amino acid sequence by virtue of which they interact only with the ANTIGEN (or a very similar shape) that induced their synthesis in cells of the lymphoid series (especially PLASMA CELLS).
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
May 1988, Lancet (London, England),
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
July 1987, British medical journal (Clinical research ed.),
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
September 1990, Lancet (London, England),
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
February 1988, Lancet (London, England),
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
January 1975, Verhandlungen der Deutschen Gesellschaft fur Pathologie,
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
June 1992, Archives of disease in childhood,
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
January 1985, Terapevticheskii arkhiv,
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
January 1983, Deutsche medizinische Wochenschrift (1946),
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
February 1983, Lancet (London, England),
G Rostoker, and S Delprato, and M Petit-Phar, and A Ben Maadi, and J Laurent, and P Lang, and B Weil, and G Lagrue
November 2010, Nephrologie & therapeutique,
Copied contents to your clipboard!